Securities Registration: Employee Benefit Plan (s-8)

Date : 05/10/2019 @ 9:51PM
Source : Edgar (US Regulatory)
Stock : Actinium Pharmaceuticals (Delaware) (ATNM)
Quote : 0.2303  -0.0097 (-4.04%) @ 10:58PM

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on May 10, 2019 

Registration No.           

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

ACTINIUM PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

DELAWARE   74-2963609
(State or other Jurisdiction of   (I.R.S Employer
Incorporation or Organization)   Identification Number)
     
275 Madison Avenue, 7 th Floor, New York, NY   10016
(Address of Principal Executive Offices)   (Zip Code)

 

ACTINIUM PHARMACEUTICALS, INC.

AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN

(Full Title of the Plan)

 

Sandesh Seth
Chairman and CEO
275 Madison Avenue, 7 th Floor
New York, New York 10016
Phone: (646) 677-3870
(Name, Address and Telephone Number of Agent for Service)

 

Copy to:

Thomas Slusarczyk, Esq.

The Matt Law Firm, PLLC

1701 Genesee Street

Utica, New York 13501

(315) 235-2299

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐   Accelerated filer ☒
Non-accelerated filer ☐   Smaller reporting company ☒
  Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

  

 

 

CALCULATION OF REGISTRATION FEE

 

Title of of securities to be registered   Amount to be
registered (1)
    Proposed maximum
offering price
per share (2)
    Proposed maximum
aggregate offering
price (2)
    Amount of
registration
fee
 
Common Stock $0.001 par value (3)     5,000,000     $ 0.2975     $ 1,487,500     $ 180.29  

  

(1) This Registration Statement also covers additional shares of Actinium Pharmaceuticals, Inc. common stock that may be issuable by reason of stock splits, stock dividends, or other adjustment provisions of the Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan, as amended, in accordance with Rule 416 under the Securities Act of 1933, as amended.
(2) Estimated solely for the purpose of calculating the registration fee computed pursuant to Rule 457(c) and (h), upon the basis of the average of the high and low prices of the common stock as quoted on the NYSE American on May 8, 2019.
(3) Represents the number of stock options and shares available for future option grants under the Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan, as amended.

 

 

 

  

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed by Actinium Pharmaceuticals, Inc. (the “Company”), pursuant to General Instruction E to the Form S-8 Registration Statement under the Securities Act of 1933, as amended, in connection with the registration of an additional 5,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) issuable pursuant to the Company’s Amended and Restated 2013 Stock Plan (as amended, the “Plan”). 17,750,000 shares of Common Stock issuable under the Plan have been previously registered pursuant to the Company’s Registration Statements on Form S-8 (File No. 333-197283, File No. 333-216746 and File No. 333-223741) filed with the Securities and Exchange Commission on July 7, 2014, March 16, 2017 and March 16, 2018, respectively. and the information contained therein is incorporated herein by reference.

 

  

 

 

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in accordance with Rule 428(b)(1) under the Securities Act.  In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. Such documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The following documents filed by the Registrant with the Commission are incorporated herein by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):

 

(a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Commission on March 15, 2019; 

 

(b) The Registrant’s Current Report on Form 8-K filed with the Commission on April 18, 2019;

 

(c)  All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, subsequent to the end of the fiscal year covered by the form referred to in (a) above; and

 

(d) The description of our common stock, which is contained in our Form 8-K/A, filed with the Securities and Exchange Commission on January 28, 2013, including any amendment or report filed for the purpose of updating such description.

 

In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

 

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

 

You may request a copy of these filings, at no cost, by writing or telephoning the Registrant at:

 

275 Third Avenue

7 th Floor

New York, NY 10016

Telephone: 646-677-3870

Attn: Investor Relations

 

You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document. 

  

1

 

 

Item 8. Exhibits.

 

Exhibit No.   Description
5.1     Opinion of The Matt Law Firm, PLLC*
23.1   Consent of Marcum LLP*
23.2   Consent of GBH CPAs, PC*
23.3   Consent of The Matt Law Firm, PLLC (included in Exhibit 5.1)*
24.1   Power of Attorney (included on signature page)*
99.1   Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan (incorporated by reference to Exhibit 10.33 to Form S-1 filed on January 31, 2014).
99.2   First Amendment to Amended and Restated 2013 Stock Plan, effective August 6, 2015 (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 7, 2015).
99.3   Second Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 15, 2015 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 16, 2015).
99.4   Third Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 22, 2015 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 11, 2016).
99.5   Fourth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 13, 2016 (incorporated by reference to Exhibit 1.1 to Form 8-K filed on December 14, 2016).
99.6   Fifth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 21, 2016 (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2017).
99.7   Sixth Amendment to the 2013 Amended and Restated Stock Plan, effective as of March 14, 2018 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 16, 2018).
99.8   Seventh Amendment to the 2013 Amended and Restated Stock Plan, effective as of March 6, 2019 (incorporated by reference to Exhibit 10.39 to Form 10-K filed on March 15, 2019).

   

* Filed herewith

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 10th day of May, 2019. 

 

  Actinium Pharmaceuticals, Inc.
     
  By: /s/ Sandesh Seth
    Name: Sandesh Seth
    Title:

Chairman & Chief Executive Officer

(Duly Authorized Officer and

Principal Executive Officer)

 

POWER OF ATTORNEY

 

Each of the undersigned directors and officers of Actinium Pharmaceuticals, Inc., a Delaware corporation, do hereby constitute and appoint Sandesh Seth the undersigned’s true and lawful attorney and agent, with full power of substitution and resubstitution in each, to do any and all acts and things in our name and on our behalf in our respective capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents, or either one of them, may deem necessary or advisable to enable said corporation to comply with the Securities Act, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this registration statement, including specifically, but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments (including post-effective amendments) hereto, and each of the undersigned does hereby ratify and confirm all that said attorneys and agents, or either one of them or any substitute, shall do or cause to be done by virtue hereof. This Power of Attorney may be executed in any number of counterparts.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature   Title   Date
         
/s/ Sandesh Seth   Chairman and Chief Executive Officer   May 10, 2019
Sandesh Seth   (Principal Executive Officer)    
         
/s/ Steve O’Loughlin   Principal Financial Officer   May 10, 2019
Steve O’Loughlin   (Principal Financial and Accounting Officer)    
         
/s/ David Nicholson   Director   May 10, 2019
David Nicholson        
         
/s/ Ajit Shetty   Director   May 10, 2019
Ajit Shetty        
         
/s/ Richard I. Steinhart   Director   May 10, 2019
Richard I. Steinhart        

 

3

 

 

INDEX TO EXHIBITS

 

Exhibit No.   Description
5.1     Opinion of The Matt Law Firm, PLLC*
23.1   Consent of Marcum LLP*
23.2   Consent of GBH CPAs, PC*
23.3   Consent of The Matt Law Firm, PLLC (included in Exhibit 5.1)*
24.1   Power of Attorney (included on signature page)*
99.1   Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan (incorporated by reference to Exhibit 10.33 to Form S-1 filed on January 31, 2014).
99.2   First Amendment to Amended and Restated 2013 Stock Plan, effective August 6, 2015 (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 7, 2015).
99.3   Second Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 15, 2015 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 16, 2015).
99.4   Third Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 22, 2015 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 11, 2016).
99.5   Fourth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 13, 2016 (incorporated by reference to Exhibit 1.1 to Form 8-K filed on December 14, 2016).
99.6   Fifth Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 21, 2016 (incorporated by reference to Exhibit 10.59 to Form 10-K filed on March 16, 2017).
99.7   Sixth Amendment to the 2013 Amended and Restated Stock Plan, effective as of March 14, 2018 (incorporated by reference to Exhibit 10.56 to Form 10-K filed on March 16, 2018).
99.8   Seventh Amendment to the 2013 Amended and Restated Stock Plan, effective as of March 6, 2019 (incorporated by reference to Exhibit 10.39 to Form 10-K filed on March 15, 2019).

   

* Filed herewith

 

4

Actinium Pharmaceuticals, Inc. (AMEX:ATNM)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Actinium Pharmaceuticals, Inc. Charts.

Actinium Pharmaceuticals, Inc. (AMEX:ATNM)
Intraday Stock Chart

Today : Tuesday 16 July 2019

Click Here for more Actinium Pharmaceuticals, Inc. Charts.

Latest ATNM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.